News

Gamida will use the money to advance its clinical programs, including the development of NiCord, an experimental treatment for patients with high risk hematological malignancies or blood cancers

The company said that the drug was being explored for the treatment of high-risk atherosclerotic cardiovascular disease. Lilly Bio-Medicines senior vice president and president David Ricks said: "We’re

The regulator has granted the filing accelerated assessment, under which it intends to provide a scientific opinion on the submission in a reduced time frame of 150 days.

Under the expanded deal, the firms will work together to develop and commercialize up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next ten years,

The study is assessing Liposomal Grb-2, combined with low-dose cytarabine (LDAC) chemotherapy in patients with advanced AML. The company has started enrollment into Cohort eight, which will complete

Opdivo can be used for treatment of NSCLC with progression on or after platinum-based chemotherapy. According to the company, patients with epidermal growth factor receptor (EGFR) or anaplastic

Adheron has developed a new technology that disrupts immune cell adhesion through Cadherin-11 (Cad-11), a cell surface protein, to develop potential treatments for various inflammatory and autoimmune diseases.

Being conducted in Sierra Leone’s Kambia district, the EBOVAC-Salone study tests a regimen consisting of two vaccine components based on AdVac technology from Crucell Holland, one of the

LAMP-vax is a next-generation DNA vaccine which can stimulate an immune response against a particular protein, injecting the DNA encoding the protein rather than the protein itself. The